Korean Journal of Clinical Oncology (대한종양외과학회지)

Korean Society of Surgical Oncology (대한종양외과학회)
권호 표지
DOI QR코드

DOI QR Code

Changing trends in clinico-pathologic characteristics and treatment outcomes in patients with gastric cancer: A single-center, public hospital, retrospective study

  • Received : 2018.08.30
  • Accepted : 2018.11.29
  • Published : 2018.12.31
⟨ Previous Next ⟩

Abstract

Purpose: We analyzed our 10-year experience in a single-center, public hospital and thereby evaluated the changing trends of clinico-pathologic and surgical characteristics as well as treatment outcomes in patients with gastric cancer. Methods: The current single-center, retrospective study was conducted with patients who had been treated at department of our medical institution during a period ranging from March 1, 2007 to June 16, 2018. The eligible patients were divided into two groups: group I (March 2007-April 2012) and II (May 2012-June 2018). Then, we compared time-dependent changes in clinico-pathologic characteristics between the two groups. Results: The mean age was $63.0{\pm}11.3$ years in group I and $65.8{\pm}10.5$ years in group II, respectively (P=0.017). The American Society of Anesthesiologist (ASA) score was 34.9% for 1 point, 38.3% for 2 points, and 26.9% for 3 points or more in group I, and 31.1% for 1 point, 52.5% for 2 points, and 16.4% for 3 points or more in group II, which was statistically significant (P=0.012). The average follow-up duration was significantly different between the two group ($39.8{\pm}39.7$ vs. $23.4{\pm}20.6$) (P<0.001). The duration of postoperative hospital stay was 1.8 days longer in group II than group I (P=0.047). Tumor depth, node metastasis and distant metastasis were significantly different between the two groups (P<0.001, P=0.009, and P=0.019, respectively). Conclusion: There were significant differences in the age, ASA score, average follow-up duration, postoperative hospital stay, tumor depth, node metastasis and distant metastasis between the two groups.

Keywords

References

  1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 2017;3:524-48. https://doi.org/10.1001/jamaoncol.2016.5688
  2. Rugge M, Genta RM, Di Mario F, El-Omar EM, El-Serag HB, Fassan M, et al. Gastric cancer as preventable disease. Clin Gastroenterol Hepatol 2017;15:1833-43. https://doi.org/10.1016/j.cgh.2017.05.023
  3. Choi IS, Choi M, Lee JH, Kim JH, Suh KJ, Lee JY, et al. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: a population-based outcomes study. PLoS One 2018;13:e0198544. https://doi.org/10.1371/journal.pone.0198544
  4. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, et al. Treatment of gastric cancer. World J Gastroenterol 2014;20:1635-49. https://doi.org/10.3748/wjg.v20.i7.1635
  5. Lazar DC, Taban S, Cornianu M, Faur A, Goldis A. New advances in targeted gastric cancer treatment. World J Gastroenterol 2016;22:6776-99. https://doi.org/10.3748/wjg.v22.i30.6776
  6. Lin WL, Sun JL, Chang SC, Wu PH, Huang WT, Tsao CJ. Factors predicting survival of patients with gastric cancer. Asian Pac J Cancer Prev 2014;15:5835-8. https://doi.org/10.7314/APJCP.2014.15.14.5835
  7. Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol 2017;39:1010428317714626.
  8. Bausys R, Bausys A, Vysniauskaite I, Maneikis K, Klimas D, Luksta M, et al. Risk factors for lymph node metastasis in early gastric cancer patients: report from Eastern Europe country- Lithuania. BMC Surg 2017;17:108. https://doi.org/10.1186/s12893-017-0304-0
  9. Marano L, Polom K, Patriti A, Roviello G, Falco G, Stracqualursi A, et al. Surgical management of advanced gastric cancer: an evolving issue. Eur J Surg Oncol 2016;42:18-27. https://doi.org/10.1016/j.ejso.2015.10.016
  10. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.
  11. Borch K, Jonsson B, Tarpila E, Franzen T, Berglund J, Kullman E, et al. Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg 2000;87:618-26. https://doi.org/10.1046/j.1365-2168.2000.01425.x
  12. Information Committee of Korean Gastric Cancer Association. Korean Gastric Cancer Association nationwide survey on gastric cancer in 2014. J Gastric Cancer 2016;16:131-40. https://doi.org/10.5230/jgc.2016.16.3.131
  13. Park IK, Oh HK, Park SH, Park JM. Short term outcomes of gastric cancer surgery in public hospital. Korean J Clin Oncol 2012;8:16-22. https://doi.org/10.14216/kjco.12012
  14. Kim H, Hwang Y, Sung H, Jang J, Ahn C, Kim SG, et al. Effectiveness of gastric cancer screening on gastric cancer incidence and mortality in a community-based prospective cohort. Cancer Res Treat 2018;50:582-9. https://doi.org/10.4143/crt.2017.048
  15. Craanen ME, Dekker W, Blok P, Ferwerda J, Tytgat GN. Time trends in gastric carcinoma: changing patterns of type and location. Am J Gastroenterol 1992;87:572-9.
  16. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-49. https://doi.org/10.1016/S1470-2045(10)70070-X
  17. Tegels JJ, De Maat MF, Hulsewe KW, Hoofwijk AG, Stoot JH. Improving the outcomes in gastric cancer surgery. World J Gastroenterol 2014;20:13692-704. https://doi.org/10.3748/wjg.v20.i38.13692
  18. Park CH, Song KY, Kim SN. Treatment results for gastric cancer surgery: 12 years' experience at a single institute in Korea. Eur J Surg Oncol 2008;34:36-41. https://doi.org/10.1016/j.ejso.2007.03.004
  19. Ahn HS, Lee HJ, Yoo MW, Jeong SH, Park DJ, Kim HH, et al. Changes in clinicopathological features and survival after gastrectomy for gastric cancer over a 20-year period. Br J Surg 2011;98:255-60. https://doi.org/10.1002/bjs.7310
  20. Lopez-Basave HN, Morales-Vasquez F, Ruiz-Molina JM, Namendys-Silva SA, Vela-Sarmiento I, Ruan JM, et al. Gastric cancer in young people under 30 years of age: worse prognosis, or delay in diagnosis? Cancer Manag Res 2013;5:31-6.
  21. Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Tatebe S, et al. Effect of age on prognosis in patients with gastric cancer. ANZ J Surg 2006;76:458-61. https://doi.org/10.1111/j.1445-2197.2006.03756.x
  22. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9. https://doi.org/10.1001/jama.1991.03460100089030
  23. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53. https://doi.org/10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2
  24. Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge. World J Gastroenterol 2015;21:11428-38. https://doi.org/10.3748/wjg.v21.i40.11428
  25. Miyahara R, Niwa Y, Matsuura T, Maeda O, Ando T, Ohmiya N, et al. Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol 2007;22:1435-42. https://doi.org/10.1111/j.1440-1746.2007.04991.x
  26. Kubota H, Kotoh T, Masunaga R, Dhar DK, Shibakita M, Tachibana M, et al. Impact of screening survey of gastric cancer on clinicopathological features and survival: retrospective study at a single institution. Surgery 2000;128:41-7. https://doi.org/10.1067/msy.2000.106812
  27. Maehara Y, Kakeji Y, Oda S, Takahashi I, Akazawa K, Sugimachi K. Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. Br J Cancer 2000;83:986-91. https://doi.org/10.1054/bjoc.2000.1427
  28. Wu CW, Hsiung CA, Lo SS, Hsieh MC, Chen JH, Li AF, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309-15. https://doi.org/10.1016/S1470-2045(06)70623-4
  29. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453-62. https://doi.org/10.1056/NEJMoa0707035
  30. Chang SC, Liu KH, Hung CY, Tsai CY, Hsu JT, Yeh TS, et al. Adjuvant chemotherapy improves survival in stage III gastric cancer after D2 surgery. J Cancer 2018;9:81-91. https://doi.org/10.7150/jca.21989